Cue Biopharma, INC. 8-K Filing
Ticker: CUE · Form: 8-K · Filed: Nov 24, 2025 · CIK: 1645460
Sentiment: neutral
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-11-24 08:08:12
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CUE Nasdaq Capital Market
Filing Documents
- cue-20251124.htm (8-K) — 66KB
- cue-ex99_1.htm (EX-99.1) — 12KB
- img239719762_0.jpg (GRAPHIC) — 613KB
- img239719762_1.jpg (GRAPHIC) — 678KB
- img239719762_2.jpg (GRAPHIC) — 375KB
- img239719762_3.jpg (GRAPHIC) — 441KB
- img239719762_4.jpg (GRAPHIC) — 349KB
- img239719762_5.jpg (GRAPHIC) — 554KB
- img239719762_6.jpg (GRAPHIC) — 346KB
- img239719762_7.jpg (GRAPHIC) — 591KB
- img239719762_8.jpg (GRAPHIC) — 531KB
- img239719762_9.jpg (GRAPHIC) — 349KB
- img239719762_10.jpg (GRAPHIC) — 395KB
- img239719762_11.jpg (GRAPHIC) — 382KB
- img239719762_12.jpg (GRAPHIC) — 499KB
- img239719762_13.jpg (GRAPHIC) — 349KB
- img239719762_14.jpg (GRAPHIC) — 437KB
- img239719762_15.jpg (GRAPHIC) — 363KB
- img239719762_16.jpg (GRAPHIC) — 234KB
- img239719762_17.jpg (GRAPHIC) — 273KB
- img239719762_18.jpg (GRAPHIC) — 516KB
- img239719762_19.jpg (GRAPHIC) — 336KB
- img239719762_20.jpg (GRAPHIC) — 372KB
- img239719762_21.jpg (GRAPHIC) — 427KB
- img239719762_22.jpg (GRAPHIC) — 401KB
- img239719762_23.jpg (GRAPHIC) — 529KB
- img239719762_24.jpg (GRAPHIC) — 67KB
- img239719762_25.jpg (GRAPHIC) — 405KB
- 0001193125-25-292093.txt ( ) — 15098KB
- cue-20251124.xsd (EX-101.SCH) — 44KB
- cue-20251124_htm.xml (XML) — 4KB
01
Item 7.01. Regulation FD Disclosure On November 24, 2025, Cue Biopharma, Inc. (the "Company") made publicly available on its website an updated corporate presentation. A copy of the presentation is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. The information in Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Corporate Presentation, dated November 24, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Cue Biopharma, Inc. Date: November 24, 2025 By: /s/ Usman Azam Name: Usman Azam Title: President and Chief Executive Officer